MediQuest touts Phase III Raynaud's data

MediQuest Therapeutics is reporting positive results from a Phase III trial of MQX-503, a topical therapy for Raynaud's Disease. Raynaud's--a stinging constriction of blood flow to hands, feet and other extremities that affects mostly women--has an estimated market potential of more than $300 million. Patients taking MQX-503 showed significant improvements in their condition.

"With the conclusion of this clinical study, MediQuest is one step closer to submitting the MQX-503 New Drug Application to the FDA," said Dr. Frederick Dechow, MediQuest president and CEO. "Our proprietary drug delivery technology provides a unique platform to deliver active therapeutic agents to specific problem areas. MQX-503 is a new therapy specifically designed to treat this unmet clinical need."

- check out the release from MediQuest
- see this Emerging Drug Developer profile for more

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.